Vivos Stock Financials

VVOS -  USA Stock  

USD 3.50  0.24  6.42%

Understanding current and past Vivos Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Vivos Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Vivos Therapeutics' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Vivos Therapeutics' financials over time to get the whole picture.
.
Please exercise analysis of Vivos Therapeutics fundamentals to determine if markets are correctly pricing the firm. We were able to break down and interpolate data for twenty-eight available drivers for Vivos Therapeutics, which can be compared to its competition. To make sure the equity is not overpriced, please validate all Vivos Therapeutics financials, including its price to sales, cash per share, as well as the relationship between the Cash per Share and short ratio . Given that Vivos Therapeutics has a shares owned by insiders of 21.77 %, we advise you to double-check Vivos Therapeutics current market performance to make sure the company can sustain itself down the road. Use Vivos Therapeutics to protect your portfolios against small market fluctuations. The stock experiences a very speculative upward sentiment. Check odds of Vivos Therapeutics to be traded at $3.33 in 90 days.

Vivos Fundamentals 

 
Refresh
With this module, you can analyze Vivos financials for your investing period. You should be able to track the changes in Vivos Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  Chance Of Financial Distress
Less than 28
Vivos Therapeutics has less than 28 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Vivos Therapeutics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Vivos Therapeutics' official financial statements usually reflect Vivos Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Vivos Therapeutics. For example, before you start analyzing numbers published by Vivos accountants, it's critical to develop an understanding of what Vivos Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Vivos Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vivos Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Vivos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vivos Therapeutics. Please utilize our Beneish M Score to check the likelihood of Vivos Therapeutics' management to manipulate its earnings.

Vivos Therapeutics Company Summary

Vivos Therapeutics competes with Abbott Laboratories, Medtronic, Stryker Corp, Edwards Lifesciences, and Boston Scientific. Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea . Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado. Vivos Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
Business Address9137 South Ridgeline
SectorHealthcare
IndustryMedical Devices
BenchmarkDOW
Websitewww.vivoslife.com
Phone866 908 4867
CurrencyUSD - US Dollar
You should never invest in Vivos Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Vivos Stock, because this is throwing your money away. Analyzing the key information contained in Vivos Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Vivos Therapeutics Key Financial Ratios

Generally speaking, Vivos Therapeutics' financial ratios allow both analysts and investors to convert raw data from Vivos Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Vivos Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Vivos Therapeutics reports annually and quarterly.

Vivos Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Vivos Therapeutics's current stock value. Our valuation model uses many indicators to compare Vivos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vivos Therapeutics competition to find correlations between indicators driving Vivos Therapeutics's intrinsic value. More Info.
Vivos Therapeutics is rated below average in number of employees category among related companies. It is rated below average in total debt category among related companies making up about  9,549  of Total Debt per Number of Employees. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Vivos Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vivos Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vivos Therapeutics' earnings, one of the primary drivers of an investment's value.

Vivos Therapeutics Systematic Risk

Vivos Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vivos Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Vivos Therapeutics correlated with the market. If Beta is less than 0 Vivos Therapeutics generally moves in the opposite direction as compared to the market. If Vivos Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vivos Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vivos Therapeutics is generally in the same direction as the market. If Beta > 1 Vivos Therapeutics moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Vivos Therapeutics Financials

What exactly are Vivos Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Vivos Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Vivos Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Vivos Therapeutics investors may use each financial statement separately, they are all related. The changes in Vivos Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vivos Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Vivos Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Vivos grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Vivos Therapeutics October 25, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Vivos Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vivos Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vivos Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Vivos Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vivos Therapeutics's daily price indicators and compare them against related drivers.
Downside Deviation4.92
Information Ratio0.0078
Maximum Drawdown55.91
Value At Risk(6.74)
Potential Upside10.61
Also, please take a look at World Market Map. Note that the Vivos Therapeutics information on this page should be used as a complementary analysis to other Vivos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Vivos Stock analysis

When running Vivos Therapeutics price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Is Vivos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vivos Therapeutics. If investors know Vivos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vivos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vivos Therapeutics is measured differently than its book value, which is the value of Vivos that is recorded on the company's balance sheet. Investors also form their own opinion of Vivos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vivos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vivos Therapeutics' market value can be influenced by many factors that don't directly affect Vivos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Vivos Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.